MIAS Pharma specialises in Clinical and Commercial QP services, along with holding Manufacturer’s/Importation Authorisations (MIAs), which enable the company to manage market importation and batch certification processes for medicinal products. Their expertise and services are highly valued in the pharmaceutical industry for ensuring regulatory compliance and maintaining high standards of quality.
The integration of MIAS Pharma into Normec not only broadens Normec’s healthcare service offerings but also reinforces its commitment to delivering comprehensive solutions to life sciences customers. The current leadership of MIAS Pharma, including owner Ann McGee and CEO Pierre Baviera will remain actively involved, ensuring a smooth transition and continued operational excellence.
Joep Bruins, founder and CEO of Normec, expressed his enthusiasm: “We are thrilled to welcome MIAS Pharma to Normec. This acquisition aligns perfectly with our strategic goals to enhance our service offerings and geographic presence in the life sciences sector. MIAS Pharma’s reputation for excellence and their specialized services will be a tremendous asset to Normec.”
Ann McGee and Pierre Baviera commented: “MIAS Pharma is delighted to announce its integration with the Normec Group, a move that will significantly enhance our capabilities and expand our service offerings. This collaboration promises to drive innovation and ensure the highest quality standards for our clients and partners.”
Normec were advised on the transaction by KPMG (financial and tax) and McCann FitzGerald LLP (legal). MIAS Pharma were advised by Addleshaw Goddard LLP.
Your partner in quality, safety, and compliance
The life sciences sector requires specialized knowledge and reliable support. With our broad expertise, we help organizations comply with laws and regulations, ensure quality, and continue to innovate with confidence.
Related services
Related articles
07 Apr 2026
MIAS Pharma will be attending the BIO International Convention in San Diego, USA
MIAS Pharma is excited to attend the BIO International convention in San Diego, California, from June 22nd – 25th 2026. Visit us at booth #4052, we’ll be happy to connect.
01 Apr 2026
Let’s Meet at SNMMI Annual meeting 2026 LA
MIAS Pharma is excited to attend the SNMMI annual meeting in Los Angeles, California, from May 30th – June 2nd 2026. Visit us at booth #1363, we’ll be happy to connect.
20 Mar 2026
Labelling & Packaging: A Core MAH Responsibility
Marketing Authorisation Holders (MAHs) carry primary responsibility for the accuracy, control, and lifecycle management of labelling and packaging across all markets where a product is placed on the EU/EEA market. This obligation extends beyond artwork creation to encompass regulatory approval, change control, supply chain implementation, and post‑market vigilance for labelling‑related quality defects and recalls.
13 Mar 2026
Getting ready for product launch with serialisation
As your medicinal product moves from the clinical space into commercial launch territory, one crucial question looms large:
06 Mar 2026
MAHs: Are Your GMP–GVP Interfaces Aligned?
Calling all Marketing Authorisation Holders (MAHs) are you set up for success? Have you confirmed whether your five‑year renewal is required? Is this critical information visible and accessible to your QPs and QPPVs?
20 Feb 2026
Quality & Regulatory Implications from EU Critical Medicines Act
The European pharmaceutical landscape is entering a period of major regulatory transformation with the introduction of not only the EU Critical Medicines Act (CMA), new pharma package.
28 Jan 2026
Navigating Evolving EU Marketing Authorisation: Are You Ready for Tomorrow’s Compliance?
As the European pharmaceutical landscape transforms, Marketing Authorisation Holders (MAHs) now face a broader – and more demanding – array of duties that stretch far beyond initial product approval. The new compliance reality encompasses critical operational areas like shortage reporting, environmental risk management, end-to-end product data maintenance, supply chain resilience, and more. These obligations often overlap with, yet are legally distinct from, manufacturing and wholesale authorisations – presenting new blind spots and risks for the unprepared.